- HLB Pep has signed a CDMO agreement with Reprocell to supply patient-specific neoantigen peptide APIs.
- The partnership focuses on personalised cancer therapies using customised peptides derived from genetic analysis.
HLB Pep has entered into a contract development and manufacturing organization (CDMO) agreement with Reprocell, a Japanese cell therapy company, to supply patient-specific neoantigen peptide active pharmaceutical ingredients. The agreement involves manufacturing customised peptides at HLB Pep’s GMP facility based on neoantigen sequences identified through patient genetic analysis.
The collaboration aims to support the development of personalised therapies by enabling rapid and precise synthesis of neoantigen-derived peptides. These peptides are designed to target cancer-specific markers unique to individual patients, allowing selective targeting of cancer cells without affecting normal tissue.
Under the agreement, HLB Pep will leverage its peptide manufacturing technology and GMP production capabilities to deliver high-purity products. The company stated that its ability to meet Japan’s quality standards supports its position in the global contract manufacturing market.
“This contract represents a meaningful achievement in gaining global recognition for our high-purity peptide manufacturing technology and GMP production capabilities.”
Shim Kyung-jae, Chief Executive Officer of HLB Pep
The companies plan to use the collaboration to expand into global markets beyond Japan. HLB Pep added that it has been increasing its manufacturing capacity to address growing demand for CDMO services in peptide-based therapies.
